Browse Category

NYSE:PEN News 13 January 2026 - 30 January 2026

Boston Scientific stock snaps a 4-day run — what to watch before Feb. 4 earnings

Boston Scientific stock snaps a 4-day run — what to watch before Feb. 4 earnings

Boston Scientific shares fell 1.6% to $92.33 Thursday, ending a four-day rally on heavy volume after the company completed its acquisition of Nalu Medical. The stock underperformed sector peers as investors awaited fourth-quarter results due Feb. 4 and looked for updates on recent deal activity, including the $14.5 billion Penumbra purchase.
Boston Scientific (BSX) stock drops after $14.5B Penumbra deal; FDA nod and earnings date ahead

Boston Scientific (BSX) stock drops after $14.5B Penumbra deal; FDA nod and earnings date ahead

Boston Scientific shares fell 4% Thursday after it announced a $14.5 billion cash-and-stock deal to buy Penumbra at $374 per share. Penumbra stock jumped 12% to $350.49. Boston Scientific warned of near-term EPS dilution and will fund about $11 billion in cash using debt and existing funds. Investors are watching for more details ahead of Boston Scientific’s earnings report on Feb. 4.

Stock Market Today

AMD stock rebounds 8% after post-earnings slump as payrolls, CPI loom

AMD stock rebounds 8% after post-earnings slump as payrolls, CPI loom

7 February 2026
AMD shares jumped 8.2% to $208.44 Friday, rebounding after a 13% plunge earlier in the week on weak guidance and AI competition fears. The Philadelphia semiconductor index rose 5.7% as chip stocks led a broader market rally. Investors are awaiting next week’s U.S. payrolls and inflation data, which could shift rate expectations for tech.
Netflix stock price ends higher as DOJ widens review of Warner deal — what to watch next week

Netflix stock price ends higher as DOJ widens review of Warner deal — what to watch next week

7 February 2026
Netflix shares rose 1.6% to $82.20 Friday as the Justice Department expanded its antitrust review of the company’s planned $82.7 billion Warner Bros Discovery acquisition. A Wall Street Journal report said investigators are probing possible anti-competitive tactics. Director Reed Hastings reported a transfer of 241,944 shares via a family trust, according to an SEC filing.
Go toTop